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Apoptosis, a genetically programmed mechanism of eliminating
cells in response to a variety of stimuli, is a widespread phenom-
enon occurring at different stages of morphogenesis, growth and
development as well as in normal turnover of adult tissues (Reed,
1994). Loss of apoptotic response in tumour cells may be one of
the mechanisms involved in malignant progression and resistance
to chemotherapy (Arends and Wyllie, 1991). Studies have shown
that several proteins are involved in the regulation of apoptosis.
Abnormalities in the expression of these proteins may contribute
to tumorigenesis by altering the balance between cell growth and
cell death (Vaux, 1993). A number of cellular and viral homo-
logues of Bcl-2 have been identified. Beyond Bcl-2 this family of
proteins includes Bcl-X, and Mcl-1 which act as blockers of apop-
tosis, whereas others such as Bax and Bak appear to promote
apoptosis (Oltvai et al, 1993). 
Structurally, Bcl-2 is an integral membrane protein localised to
membranes of the nucleus and endoplasmic reticulum. The protein
product of the Bax gene, which has 21% homology to the Bcl-2
protein, can form heterodimers with Bcl-2 leading to abrogation of
its ability to suppress apoptosis (Oltvai et al, 1993). In its long
splice variant (Bcl-XL), Bcl-X is another potent antagonist of
apoptosis, whereas the short splice variant (Bcl-XS) promotes cell
death. Recent studies demonstrated that Bcl-XL is mainly involved
in the mechanism of resistance to chemotherapeutic agents and
radiation (Datta et al, 1995). An abnormal pattern of Bcl-2, Bax
and Bcl-X expression has been demonstrated in several human
malignancies (McDonnel et al, 1992; Gazzaniga et al, 1996;
Krajewska et al, 1996a,b; Xie et al, 1998). 
Wilms’ tumour, or nephroblastoma, is a paediatric malignancy
of the kidney and one of the most common solid tumours in chil-
dren (Beckwith, 1994). Preoperative chemotherapy as treatment
for Wilms’ tumour has increasingly been more used in Europe by
International Society of Paediatric Oncology (SIOP) which is
different from the protocol used in the USA by the National
Wilms’ Tumour Study (NWTS) (D’Angio, 1983). Despite the
remarkable response to chemotherapy, 5% to 10% of tumours are
fatal due to metastases and/or the occurrence of drug resistance
(Green et al, 1994). Since it appears that programmed cell death is
a crucial event in normal kidney development one may expect
oncogenic events to result from defects in the pathways of renal
cell death (Coles et al, 1993). Therefore, the prognostic value of
Bcl-2, Bax and for Bcl-XS/L were investigated in specimens of
nephroblastoma patients which were chemotherapeutically treated
prior to surgery. Having access to this type of material derived
from a substantial number of patients with a good stage distribu-
tion, the aim of our study was to find factors which could predict
the clinical outcome of these patients after being treated by
chemotherapy and surgery. 
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Summary Apoptotic cell death represents an important mechanism for the precise regulation of cell numbers in normal tissues. Various
apoptosis-associated regulatory proteins, such as Bcl-2, Bax and Bcl-X, may contribute to the rate of apoptosis in neoplasia. The present
study was performed to evaluate the prognostic value of these molecules in a group of 61 Wilms’ tumours of chemotherapeutically pre-treated
patients using an immunohistochemical approach. Generally, Bcl-2, Bax and for Bcl-XS/L were expressed in the blastemal and epithelial
components of Wilms’ tumour. Immunoreactive blastema cells were found in 53%, 41% and 38% of tumours for Bcl-2, Bax and for Bcl-XS/L,
respectively. An increased expression of Bcl-2 was observed in the blastemal component of increasing pathological stages. In contrast, a
gradual decline of Bax expression was observed in the blastemal component of tumours with increasing pathological stages. Also blastemal
Bcl-XS/L expression decreased with stage. Univariate analysis showed that blastemal Bcl-2 expression and the Bcl-2/Bax ratio were indicative
for clinical progression, whereas epithelial staining was of no prognostic value. Multivariate analysis showed that blastemal Bcl-2 expression
is an independent prognostic marker for clinical progression besides stage. These findings demonstrate that alterations of the Bcl-2/Bax
balance may influence the clinical outcome of Wilms’ tumour patients by deregulation of programmed cell death. © 2001 Cancer Research
Campaign http://www.bjcancer.com
Keywords: Wilms’ tumour; Bcl-2; Bax; Bcl-X; prognosis 
1557
Received 11 September 2000 
Revised 31 August 2001 
Accepted 31 August 2001 
Correspondence to: GJ van Steenbrugge 
British Journal of Cancer (2001) 85(10), 1557–1563
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.2146, available online at http://www.idealibrary.com on  http://www.bjcancer.comMATERIALS AND METHODS 
Patients 
During the period 1987–1999, 61 patients with nephroblastoma
were treated by neo-adjuvant chemotherapy and subsequent
tumour nephrectomy. Following treatment patients were followed
regularly and all data concerning diagnosis, treatment and follow-
up were stored in a database. Clinical progression was defined as
histologically or cytologically proven local recurrence or the
appearance of distant metastases. 
Sample selection 
All nephrectomy specimens were fixed in 10% buffered formalin
and embedded in paraffin. The haematoxylin and eosin-stained
slides were reviewed by an experienced paediatric pathologist
(JCDH). The tumour stage (pT stage) was assigned according to
adaptation of the SIOP trial protocol established in the SIOP
meeting in Stockholm in 1994 (Boccon-Gibod, 1998). Among the
paraffin blocks available of individual patients those containing
tissue with the 3 different cell types of Wilms’ tumour (blastemal,
epithelial and stromal) were selected. In addition, adjacent normal
kidney tissue was taken from each patient. 
Antibodies 
The following primary antibodies were used: mouse monoclonal
antibody against Bcl-2 (clone 124) (DAKO, A/S, Glostrup,
Denmark) and rabbit anti-human Bax (P-19) and Bcl-XS/L (S-18
against both the Bcl-XL and Bcl-XS) polyclonal antibodies from
Santa Cruz, California, USA. The specificity and characteristics of
these antibodies have been published elsewhere (Oltvai et al,
1993; Datta et al, 1995). 
Immunohistochemistry 
The PAP (peroxidase-anti-peroxidase) technique was used. Serial
sections (5 µ m) from all samples were mounted on 3-aminopropyl-
trietoxysilane (Sigma Co, St Louis, MO, USA) coated glass slides,
which were incubated overnight in a 60˚C incubator. After
dewaxing in fresh xylene for 10 min and passage in 100%
methanol for 10 min, the sections were rinsed in methanol
containing 3% hydrogen peroxide for 20 min to block endogenous
peroxidase activity. The slides were rinsed with distilled water. In
order to enhance antigen exposure, the slides were microwaved at
700 W in 0.1 M citrate buffer at pH 6.0 for 15 min. After cooling
and rinsing with PBS, the slides were placed in a Sequenza
immunostaining system (Shandon, Uncorn, UK). Sections were
incubated with 10% normal rabbit serum (prior to monoclonal anti-
body) or 10% normal goat serum (prior to polyclonal antibody)
(DAKO). Incubation was done in PBS/5% bovine serum albumin
(BSA) for 15 min and subsequently overnight with the primary
antibody at 4˚C. The antibodies were diluted in PBS/5% BSA at 1:50
for Bcl-2, 1: 150 for Bax and 1:75 for Bcl-XS/L. Subsequently, the slides
were rinsed with PBS/Tween (0.1%) and incubated for 30 min with
rabbit-anti-mouse antibody for monoclonal antibody or goat-anti-
rabbit for polyclonal antibody (DAKO), followed by rinsing with
PBS/Tween (0.1%). The PAP complex (DAKO) was diluted in
PBS/5% BSA at 1:300 and incubated for 30 min followed by rins-
ing with PBS. The antigen-antibody binding was visualised with
diaminobenzidine tetrahydrochloride dihydrate (Fluka, Neu-Ulm,
Germany) as chromogen. The sections were lightly counterstained
with haematoxylin. Negative controls were included by replacing
the primary antibody by PBS/5% BSA. Normal kidney tissue adja-
cent to the tumour served as positive control. 
Immunostaining analysis 
The slides were examined at 25 × magnification without know-
ledge of the clinical outcome of the patients. The amount of 
positive staining was assessed as the estimated percentage posi-
tively staining cells: < 10% was considered negative, > 10% was
considered positive. 
Statistical analysis 
Statistical analysis was performed using the SPSS 9 software
package. The association between Bcl-2, Bax, Bcl-XS/L expression
and clinico-pathological features was analysed using χ 2 test. For
analysis of survival data Kaplan–Meier curves were constructed
and the log-rank test was performed. Multivariate analysis was
performed using Cox’s proportional hazards model with P < 0.05
considered statistically significant. 
Protein extraction and Western blot analysis 
To further confirm the Bcl-XS/L immunohistochemical data, Western
analysis was performed with tissues from Wilms’ tumour xenografts.
6 different xenograft tissues were analysed in total. Tissues 1–3 (cf.
Figure 4) originate from transplants of three individual patients,
resulting in xenografts WT-7, WT-9 and WT-11, respectively,
whereas tissues 4–6 (WT-15, WT-15LN, WT-16) were from one
individual patient, being a specimen of primary tumour in right
kidney (WT-15), lymph node metastasis (WT-15LN), and primary
tumour in left kidney (WT-16), respectively. Morphologically, all 6
tissues contained the blastemal and stromal component, whereas in
tissue 1 and 3 epithelial cells were present as well. The frozen tissues
were crushed in a liquid nitrogen chilled metal cylinder. The tissue
homogenates were transferred to a lysis buffer consisting of 10 mM
TRIS (pH 7.4), 150 mM NaCl (Sigma), 1% triton × 100 (Merck,
Darmstadt, Germany), 1% deoxycholate (Sigma), 0.1% sodium
dodecyl sulfate (SDS, Gibco BRL), 5 mM EDTA (Merck) and
protease inhibitors (1 mM phenylmethyl-sulfonyl fluoride, 1 mM
aprotinin, 50 mg l–1 leupeptin, 1 mM benzamidine and 1 mg l–1
pepstatin, all from Sigma). The samples were spun at 35 000 gat 4˚C
for 10 minutes. The protein content of the supernatant was measured
photometrically using the bio-rad protein assay (Bio-rad, München,
Germany). The proteins were transferred to a SDS-polyacrylamide
gel and electrophoresis was performed in 10 times diluted tray buffer
for 2 hours. The gel was blotted to a 0.45 µ m cellulose nitrate
membrane (Scheicher & Schuell, Dassel, Germany). Pre-stained
markers were used as size standards (Novex, San Diego, CA). The
immunoblot was blocked for 1 hour with 5% dry milk (Sigma) in
0.1% Tween-20 (Sigma). The antibodies were diluted 1:1000 in 5%
dry milk and applied overnight at 4˚C. After rinsing with PBS/0.1%
Tween, the blot was incubated with horseradish peroxidase-labelled
goat-anti-rabbit (1:2000, DAKO) for 1 hour. Subsequently, a one
minute incubation with a 1:1 mixture of luminol and oxidizing
reagent (DuPont NEN, Chemiluminescence kit, Boston, MA) was
performed. Excess reagent was removed by placing the blot on a
piece of Whatmann paper. Finally, the antibodies were visualised by
exposure of the blot to an X-ray film for 30 seconds. 
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Clinico-pathological findings 
The tumour-stage distribution was T1 in 21, T2 in 20 and T3 in 20
patients. There were 29 (48%) females and 32 (53%) males. The
mean age at surgery was 4.2 years, and the mean overall follow-up
period was 5.7 years. Clinical progression occurred in 14 patients
(23%), and 8 patients (13%) died from their tumour. At the end of
the follow-up period 53 patients were alive. 
BCL-2, BAX, BCL-XS/L expression in normal renal
tissues 
Immunoreactivity for Bcl-2 was found in the Henle’s loop,
collecting ducts and parietal layer of Bowman’s capsule of the
normal kidney (Figure 1A). Immunoreactivity for Bax was found
in the proximal and distal convoluted tubules and parietal layer of
Bowman’s capsule, but was not expressed in the collecting ducts
(Figure 1B). Expression of Bcl-XS/L was evident mainly in the
collecting duct and to lesser extent in the proximal and distal
convoluted tubules, whereas expression in the glomeruli was not
found (Figure 1C). 
BCL-2 expression in Wilms’ tumour tissues 
Bcl-2 positive (i.e. > 10% stained) blastemal and epithelial cells were
found in 32 (53%) and 33 (54%) of the Wilms’ tumours studied,
respectively (Table 1) Bcl-2 staining was mainly perinuclear, but
some cytoplasmic staining was also found (Figure 1D). Some speci-
mens showed expression of the majority of cancer cells, whereas in
Bcl-2 family proteins and nephroblastoma prognosis 1559
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Figure 1 Normal renal tissue sections and nephroblastoma tissues were immunostained for Bcl-2 (A, D); Bax (B, E); Bcl-XS/L (C, F), respectively. Slides were
counterstained with haematoxylin (magnification 400 × ) others only small areas of the tumour were found positive for the
Bcl-2 protein. The majority of the infiltrating lymphocytes in the
tumour stroma were strongly Bcl-2 positive, serving as internal
control for the staining procedure. Bcl-2 expression gradually
increased from T1, T2 to T3 for both the blastemal and epithelial
component. No statistically significant relationship between stage
and Bcl-2 expression was found. The nephroblastoma sections
showed an intense expression of the epithelium with little expression
in the stromal component. 
BAX expression in Wilms’ tumour tissues 
Blastemal and epithelial expression of Bax was found in a similar
percentage of Wilms’ tumours (41 and 43% of cells, respectively)
(Table 1). Bax staining was mainly cytoplasmic (Figure 1E) and the
staining pattern of most of the specimens was weak to moderate. Bax
expression in both blastema and epithelium gradually decreased from
T1 to T3, but the trend was not statistically significant. The epithelial
component of the tumour demonstrated diffuse expression of Bax. 
BCL-XS/L expression in Wilms’ tumour tissues 
Blastemal and epithelial expression of Bcl-XS/L was found in 23
(38%) and 35 (57%) of the Wilms’ tumour studied, respectively
(Table 1). The percentage of tumours with Bcl-XS/L-positive
blastema was generally lower than those staining positive for Bcl-2.
The majority of Bcl-XS/L-positive tumours had very intense cyto-
plasmic staining pattern, showing a more widely distribution
(Figure 1F). There was no statistically significant relationship
between stage and Bcl-XS/L expression. 
Immunoblot analysis of tissue lysates of a panel of human Wilms’
tumour xenografts identified the specificity of the Bcl- XS/L antibody
used for immunohistochemistry (Figure 4). Morphologically, all 6
tissues contained blastemal and stromal component, whereas in
tissue 1 and 3 epithelial cells were present as well. The Bcl-XL
protein was found to have migrated as a doublet of proteins with an
apparent molecular mass of 28–32 kDa. The Bcl-XL was clearly
detectable in all 6 samples analysed, particularly the 32 kDa
message. A clear 22 kDa band compatible with Bcl-XS was detected
in 3 samples positive for Bcl-XL, whereas faint bands were found in
the remaining 2 samples, of which one was devoid of Bcl-XS
(Figure 4). 
Prognostic value of BCL-2, BAX and BCL-XS/L
Univariate analysis using the logrank test showed a prognostic
value of blastemal Bcl-2 expression for clinical progression (Table
2, Figure 2). The blastemal expression for both Bax and Bcl-XS/L
and epithelial expression of the 3 proteins did not show any prog-
nostic value (Table 2). To test whether Bcl-2, Bax and Bcl-XS/L
expression had any prognostic impact a multivariate Cox’ regres-
sion analysis was done including the parameters pT stage, Bcl-2,
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Figure 2 Kaplan–Meier curves showing the relationship between blastemal
Bcl-2 expression and clinical progression. Censored patients are indicated by
tic marks along their line. Number of patients per group is shown between
brackets 
Table 1 Relationship between pT stage and blastemal and epithelial expression 
Bcl-2 Bax Bcl-XS/L Stage
Blastema Epithelial Blastema Epithelial Blastema Epithelial
T1 9 (15) 9 (15) 10 (16) 10 (16) 9 (15) 13 (21) 
T2 11 (18) 12 (20) 9 (15) 10 (16) 8 (13) 13 (21) 
T3 12 (20) 12 (20) 6 (10) 7 (11) 6 (10) 9 (15) 
Total 32 (53) 33 (54) 25 (41) 27 (44) 23 (38) 35 (57) 
P value > 0.05 > 0.05 > 0.05 
Data are presented as numbers, percentages between brackets.
Table 2 Univariate analysis of prognostic markers 
Blastemal Epithelial 
Variable Clinical progression Tumour-specific survival Clinical progression Tumour-specific survival 
χ 2 P* χ 2 P* χ 2 P* χ 2 P*
Bcl-2 7.31 0.006 3.32 0.07 0.01 0.94 1.09 0.29 
Bax 1.11 0.29 1.02 0.31 1.79 0.19 0.26 0.61 
Bcl-XS/L 0.52 0.47 1.22 0.27 1.44 0.23 0.63 0.43 
Bcl-2/Bax 10.31 0.02 4.56 0.21 1.92 0.59 1.33 0.72 
*Log-rank test. Bax and Bcl-XS/L expression. PT stage was divided as pT1-2 vs.
pT3. In that analysis, only the Bcl-2 blastemal expression could be
identified as independent prognostic variable besides stage (data
not shown). 
Prognostic value of the Bcl-2/Bax ratio 
By examining the Bcl-2 to Bax ratio versus outcome, 4 patients
groups were identified. The Kaplan–Meier curves of Figure 3
show the prognostic influence of Bcl-2/Bax expression on the time
to progression. Clearly, patients with high (>10%) expression of
both Bcl-2 and Bax had a statistically significant poor prognosis
compared to the 2 groups of patients with Bcl-2- negative expres-
sion (i.e., Bcl-2 and Bax negative or Bcl-2 negative/Bax positive)
(Table 2, Figure 3). Generally, the data of Figure 3 is consistent
with the notion that the patients with low Bcl-2/Bax ratio do better
than those with high ratio. Bcl-2 and Bax were simultaneously
expressed in 28% and 25% of blastemal and epithelial components
of tumours, respectively. 
DISCUSSION 
Over the past few years, Bcl-2 has moved from being a molecule
exclusively implicated in lymphoid translocation (14; 18) to being
an important gene involved in key mechanisms in the regulation of
cell death, by inhibiting apoptosis. Consequently, Bcl-2 is impli-
cated in the process of multidrug resistance of cancer. For this
reason, studying the prognostic value of Bcl-2 gene family in
malignant processes is warranted. In the present study we have
examined the expression of Bcl-2 and some of its related proteins,
Bax and Bcl-XS/L, to study its prognostic value in Wilms’ tumour.
All patients studied received chemotherapy before operation. It is
realised that in the majority of patients having a good response
upon chemotherapy, treatment did affect the cellular compartments
of the Wilms’ tumour, the blastema in particular. Consequently,
this may influence the (Bcl-2, Bax, and Bcl-XS/L) immunopheno-
type of the remaining tumour component. The present study did
not allow comparative studies of the effect of treatment upon the
expression of the apoptotic markers studied. The expression level
of the various markers, however, reflects the status of the tumour
after chemotherapy, regardless of the occurrence of drug resis-
tance. Therefore the final status of the tumour removed, may
predict the clinical outcome of the patient, e.g. whether metastasis
will occur. 
Expression of Bcl-2, Bax and Bcl-XS/L was found in normal
kidney tissues, which were used as internal positive controls for
the immunohistochemical reaction (Figure 1A, B, C) as well as for
the Western blot (Figure 4). In general, increased Bcl-2 expression
was related to advanced disease. Reduction of Bax immuno-
staining in high-stage tumours inconsistent with the more aggres-
sive character of these tumours. Most clinically oriented studies on
Bcl-2 expression have found a positive correlation with adverse
prognosis in a variety of solid tumours, including non-small-cell
lung carcinoma (Pezzella et al, 1993), nasopharyngeal carcinoma
(Lu et al, 1993), prostatic carcinoma (McDonnel et al, 1992), and
neuroblastoma (Castle et al, 1993). In contrast, Bcl-2 expression
was correlated with favourable prognosis in tumours arising from
epithelial as in stage II colon carcinoma (Sinicrope et al, 1995) and
node-positive treated breast cancer (Gasparini et al, 1995).
However, in other studies of patients with renal cell tumours (Paraf
et al, 1995), invasive transitional cell carcinoma of the bladder
(Glick et al, 1996), and head and neck cancer (Drenning et al,
1998), such correlation was not found. A recent study failed
to demonstrate prognostic Bcl-2 significance in Wilms’ tumour
because of a limited number of cases studied (Re et al, 1999). In
another study, Tanaka et al (1999) showed that preoperative
chemotherapy did not significantly influence either the occurrence
of apoptosis or expression of Bcl-2 in a group of treated Wilms’
tumour patients. In the present study, a prognostic value of
blastemal Bcl-2 expression was found for clinical progression. The
mechanism by which Bcl-2 contributes to the progression of
nephroblastoma is unknown. Based on gene transfer experiments
(Vaux et al, 1988) and studies of transgenic mouse models
(Strasser et al, 1990), Bcl-2 functions by inhibiting cell death
rather than affecting the rate of cell proliferation. 
Bcl-2 family proteins and nephroblastoma prognosis 1561
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Figure 3 Kaplan–Meier curves showing the relationship between clinical
progression and blastemal ratio of Bcl-2/Bax. Censored patients are
indicated by tic marks along their line. Number of patients per group is shown
between brackets 
Figure 4 Immunoblot analysis of Bcl-XS/L proteins in nephroblastoma tissues derived of 6 human xenografts models (lanes 1–6) and normal kidney (lane 7)
with approximate indication of size marker 
Bcl-XI
Bcl-XS
32 kDa
29 kDa
20 kD a
7 6 5 4 3 2 1Information regarding the prognostic significance of Bax in
human tumours is scarce. It has, however, been shown that reduced
Bax expression correlates with poor prognosis in patients treated
with chemotherapy for metastatic breast adenocarcinomas
(Krajewski et al, 1995) and in radiotherapeutic glottic squamous
cell carcinomas (Xie et al, 1998). High levels of Bax expression
correlates to a better outcome for patients with low-grade tumour of
urinary bladder (Gazzaniga et al, 1996). Bax expression alone had
no influences upon survival of stage I patients with radically
resected non-small-cell lung cancer (Apolinario et al, 1997),
however, a study of the Bax mRNA expression levels in nephro-
blastoma, was not indicative that its expression could have a role in
the prognosis (Re et al, 1999). This was confirmed by the outcome
of the present study showing an absence of any prognostic value of
Bax. The ratio between the Bcl-2 and the Bax proteins has been
described as a cellular rheostat determining the cellular response to
apoptotic stimuli (Oltvai et al, 1993). Given the potential role of
these proteins in malignant tumours, the prognostic significance of
combined Bcl-2 and Bax expression has been studied by many
authors. Gazzaniga et al (1996) demonstrated that the Bcl-2/Bax
expression ratio had prognostic impact for disease progression in
low-grade bladder tumours. Interestingly, in nephroblastoma Bcl-
2/Bax expression had prognostic significance for the prediction of
clinical progression at univariate analysis. 
The present data demonstrate that the level of Bcl-2 expression
exceeds that of Bcl-XS/L, although Bcl-XS/L staining is extensive
and intensive compared to Bcl-2. These results are not similar to
those reported for untreated prostatic and gastric cancer, in which
Bcl-XS/L immunoreactivity was found in 100 and 85% of the
tumours, respectively (Krajewska et al, 1996a,b). Bcl-XS/L was
expressed in 100% of untreated gliomas, but not related to the
response to radiotherapy or chemotherapy (Rieger et al, 1998). In
the present study, Western blot analysis demonstrated that the anti-
apoptotic Bcl-XL protein was the dominant isoform of the Bcl-XS/L
protein in experimental human nephroblastoma. This was in
agreement with the outcome of studies of Re et al suggesting the
oncogenic potential of Bcl-XL overexpression in the development
of anaplastic Wilms’ tumour (Re et al, 1999). Accordingly, reduc-
tion of Bcl-XL expression may influence the outcome of patients
treated with radiotherapy and/or chemotherapy (Datta et al, 1995;
Krajewska et al, 1996b; Decaudin et al, 1997). On the basis of the
present non-quantitative immunohistochemical data of various
apoptosis-associated proteins no conclusion can be drawn with
respect to the clinical behaviour of Wilms’ tumours. Still, reduc-
tion of the expression of the anti-apoptotic Bcl-XL protein, may
contribute to enhanced sensitivity to radiotherapy/chemotherapy.
Indeed, cumulating in vitro data suggest that Bcl-XL may play an
important role in the susceptibility of tumour cells to chemothera-
peutic agents and radiation. For this experimental study it seems
that the immunohistochemical expression of one single marker
will provide sufficient information on the chemosensitivity or
radiosensitivity. 
In conclusion, Bcl-2, Bax and Bcl-XS/L were expressed in
normal renal tissues and in nephroblastoma. Bcl-2 expression and
the Bcl-2/Bax ratio showed prognostic value in the specimens of
chemotherapeutically treated Wilms’ tumour patients. 
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